CD24 and neoplasm: We anticipate that a bimodal approach using a CD24-targeted FIGS contrast agent with antibody–drug conjugates, immune blockade, or immunostimulatory CARs may link precision surgical therapy with the postsurgical irradiation of unresected tumor deposits, ultimately benefiting cancer patients.